Claims for Patent: 9,796,986

Summary for Patent: 9,796,986

Title:	Serum-free stable transfection and production of recombinant human proteins in human cell lines
Abstract:	The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
Inventor(s):	Schroeder; Carola (Heidelberg, DE), Ding; Haiyan (Munich, DE), Wegmann; Cathleen (Munich, DE)
Assignee:	OCTAPHARMA AG (Lachen, CH)
Application Number:	15/369,068
Patent Claims:	1. A transfection vector comprising (a) an origin of replication, (b) a nucleic acid sequence encoding a human plasma protein selected from a blood clotting factor, a growth factor, a colony-stimulating factor (CSFs), a cytokine, an immunoglobulin, a protease, a protease inhibitor, a transport protein, a hormone, an inhibitory or regulatory acting protein, and derivatives and mutants thereof, (c) a promoter, and (d) a bovine growth hormone polyadenylation (poly (A)) signal. 2. The vector of claim 1, wherein (i) the promoter is selected from a viral promoter, a housekeeping gene promoter, and a tissue specific promoter; and/or (ii) the origin of replication allows the replication and amplification of the plasmid in bacteria; and/or (iii) the vector further carries at least one gene for a selection marker and/or is under control of the promoter as defined in (i) above; and/or (iv) the vector further carries one or more further regulatory elements. 3. The vector of claim 1, wherein said promoter and poly(A) signal are linked to the 5' and 3' end of the gene encoding said human target protein, respectively. 4. The vector of claim 1, wherein said human plasma protein is selected from factor IX as encoded by bps 939 to 2324 of SEQ ID NO: 1, human A1AT as encoded by bps 913 to 2259 of SEQ ID NO: 2, wild-type factor VIII as shown in SEQ ID NO: 9, B-domain deleted human factor VIII as encoded by bps 783 to 5162 of SEQ ID NO: 3, factor VII/VIIa as encoded by SEQ ID NOs: 13 and 14, G-CSF as encoded by SEQ ID NOs: 15, 16 and 17, and vWF as encoded by SEQ ID NO: 18. 5. The vector of claim 1 comprising a CMV promoter, a hygromycin gene, a poly(A) sequence and the gene of interest and, optionally, wherein the vector is derived from the pcDNA3.1 vector having the sequence of SEQ ID NO: 4 or 5. 6. The vector of claim 1 having the nucleic acid sequence shown in SEQ ID NO: 1, 2, 3 or 22. 7. The vector of claim 1 used for stably transfecting an immortalized human host cell line under serum-free conditions. 8. The vector of claim 7, wherein said immortalized human host cell line is selected from the group consisting of kidney, bladder, liver, lung, cardiac muscle, smooth muscle, ovary and gastrointestinal cells. 9. The vector of claim 8, wherein the kidney cells are human fetal kidney cells. 10. The vector of claim 7, wherein stably transfecting said immortalized human host cell line under serum-free conditions is effected in suspension culture without serum (a) with a cationic transfection agent or calcium phosphate, optionally using FuGENE or Lipofectamine reagent. 11. The vector of claim 7, wherein stably transfecting said immortalized human host cell line under serum-free conditions is effected in suspension culture without serum by way of an electroporation-based transfection method. 12. A method for preparing an immortalized human cell line stably transfected with a nucleic acid sequence encoding a human plasma protein selected from a blood clotting factor, a growth factor, a colony-stimulating factor (CSF), a cytokine, an immunoglobulin, a protease, a protease inhibitor, a transport protein, a hormone, an inhibitory or regulatory acting protein, and derivatives and mutants thereof, the method comprising: (i) transfecting an immortalized human host cell line under serum-free conditions with the vector of claim 1, and (ii) selecting for stably transfected cells. 13. The method of claim 12, wherein said immortalized human host cell line is selected from the group consisting of kidney, bladder, liver, lung, cardiac muscle, smooth muscle, ovary and gastrointestinal cells. 14. The method of claim 13, wherein the kidney cells are human fetal kidney cells. 15. The vector of claim 1 wherein the blood clotting factor is selected from the group consisting of factor IX, factor VIII either wild-type or B-domain deleted, factor VII/VIIa, and von Willebrand factor (vWF), the growth factor is erythropoietin, the colony-stimulating factor (CSF) is selected from the group consisting of granulocyte stimulating factor (G-CSF), macrophage CSF (M-CSF) and granulocyte-macrophage CSF (GM-CSF), the cytokine is interleukin, the protease is chymotrypsin, and the protease inhibitor is alpha-1-antitrypsin (A1AT). 16. The vector of claim 2 wherein the promoter is selected from the group consisting of a CMV promoter with or without intron A, a SV40 promoter, an EF1alpha promoter, an HSV TK promoter; and/or the selection marker is selected from the group consisting of hygromycin resistance, neomycin resistance, aminoglycoside phosphotransferase resistance, bleomycin resistance, and xanthine-guanine phosphoribosyltransferase resistance, and/or the regulatory elements are selected from the group consisting of splice sites, recombination sites, poly(A) sites, enhancers, multicloning sites, and prokaryotic plasmid sequences. 17. The vector of claim 9 wherein the kidney cells are fetal human kidney cells selected from the group consisting of 293 cells, 293T cells, and FreeStyle 293 cells. 18. The method of claim 12 wherein the blood clotting factor is selected from the group consisting of factor IX, factor VIII either wild-type or B-domain deleted, factor VII/VIIa, and von Willebrand factor (vWF), the growth factor is erythropoietin, the colony-stimulating factor (CSF) is selected from the group consisting of granulocyte stimulating factor (G-CSF), macrophage CSF (M-CSF) and granulocyte-macrophage CSF (GM-CSF), the cytokine is interleukin, the protease is chymotrypsin, and the protease inhibitor is alpha-1-antitrypsin (A1AT). 19. The method of claim 14, wherein the kidney cells are human fetal kidney cells selected from the group consisting of 293 cells, 293T cells, and FreeStyle 293 cells. 20. The vector of claim 16 wherein the aminoglycoside phosphotransferase resistance is to a compound selected from the group consisting of neomycin, G418, and APH; the bleomycin resistance is to a compound selected from the group consisting of phleomycin, bleomycin, and zeocin; and the xanthine-guanine phosphoribosyltransferase resistance is to a compound selected from the group consisting of XGPRT and gpt.

Details for Patent 9,796,986

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-06-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-06-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-06-30